Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial.
Anna Maria Di GiacomoAlessia CovreFrancesca FinotelloDietmar RiederRiccardo DanielliLuca SigalottiDiana GiannarelliFlorent PetitprezLaetitia LacroixMonica ValenteOrnella CutaiaCarolina FazioGiovanni AmatoAndrea LazzeriSanta MonterisiClelia MiraccoSandra CoralAndrea AnichiniChristoph BockAmelie NemcAram OganesianJames LowderMohammad AzabCatherine Sautès-FridmanZlatko TrajanoskiMichele MaioPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Treatment of guadecitabine combined with ipilimumab is safe and tolerable in advanced melanoma and has promising immunomodulatory and antitumor activity.